BURST CME: Report from San Francisco on Advances in HER2-Targeted Approaches in Gastrointestinal Cancers

Release Date: March 31, 2020
Expiration Date: September 30, 2020

Activity Overview

This brief online education activity is designed to provide information on the current HER2-targeted treatment paradigms, under clinical investigation for GI cancers. This activity is presented in a multimedia format that includes an audio interview with Dr David Ilson.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Daiichi Sankyo, Inc.

Target Audience

This educational program is directed toward medical oncologists, surgical oncologists, radiation oncologists, hepatologists, pathologists, and gastroenterologists interested in the treatment of gastrointestinal (GI) cancers. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with GI cancers are invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

• Assess data from clinical trials exploring HER2-targeted treatments for patients with GI malignancies
• Apply HER2-targeted therapies in clinical practice for the treatment of patients with GI malignancies

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

David H. Ilson, MD, PhD
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant Research Support: Astellas Pharma, Taiho Oncology; Consultant: Amgen, AstraZeneca, Astellas Pharma, Bayer, Bristol Myers Squibb, Eli Lilly, Merck, Pieris Pharmaceuticals, Roche, Taiho Oncology.

The staff Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.